Bioventus Q3 revenue up 15% to $139M; raises FY2024 guidance midpoint

Bioventus Inc.

2024-Q3 EPS reported -$0.52 revenue$419,638,000

Q3 revenue $139.0M (+15.0% YoY); net loss improved to $5.4M from $8.8M; Adjusted EBITDA $23.6M (+8.4%).
Non-GAAP EPS $0.06 vs $0.05; GAAP loss per share $0.07 vs $0.12.
Pain Treatments +16.7%, Surgical Solutions +18.5%, Restorative Therapies +1.2% (all YoY).
Agreed to divest Advanced Rehabilitation Business for up to $45M; close expected late 2024/early 2025; proceeds to reduce debt.
FY2024 guidance: net sales $562-567M, Adj. EBITDA $104-107M, Non-GAAP EPS $0.40-0.42 (midpoints raised).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.